Volume 12, Issue 2 (10-2024)
J Surg Trauma 2024, 12(2): 68-72 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Alavi Foumani S A, Samidoust P, Yaghoubi T, Delpasand K, Mesbah S S. Frequency of Medication Use among Liver Transplant Candidates and Recipients during the COVID-19 Pandemic. J Surg Trauma 2024; 12 (2) :68-72
URL: http://jsurgery.bums.ac.ir/article-1-439-en.html
URL: http://jsurgery.bums.ac.ir/article-1-439-en.html
Seyyed Ali Alavi Foumani 
, Pirouz Samidoust * , Tofigh Yaghoubi , Kourosh Delpasand , Seyyed Sina Mesbah
, Pirouz Samidoust * , Tofigh Yaghoubi , Kourosh Delpasand , Seyyed Sina Mesbah
Inflammatory Lung Diseases Research Center, Razi Hospital, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran
Abstract: (224 Views)
Introduction: The liver is recognized as a primary target in COVID-19 due to its susceptibility to viral infection and its prominent role in the body’s immune and metabolic responses. The present study aims to investigate the frequency of supplement and medication use among liver transplant recipients and candidates during the COVID-19 pandemic.
Methods: This cross-sectional study included demographic and clinical information from 170 liver transplant recipients and candidates who had sought care at the Guilan Transplant Center in Rasht, Iran. The participants' history of taking supplements, antibiotics, immunosuppressants, antiviral and gastrointestinal medications, and their COVID-19 infection history were recorded. Statistical analysis of the data was performed using SPSS software (version 22).
Results: Of the total 170 individuals in the study, 84(49.4%) were candidates for liver transplants, while 86(51.6%) had already received liver transplants. Among liver transplant candidates, 2(2.4%) were infected with COVID-19, and one died; among the liver transplant recipients, 8(9.3%) patients had COVID-19, and three died. Among liver transplant recipients, the most frequently consumed supplements, immunosuppressive, antibiotics, antiviral, and gastrointestinal medications were Vitamin D (77.9%), Prednisolone (90.1%), Cotrimoxazole (5.8%), Tenofovir (16.8%), and Pantoprazole (74.4%), respectively. Among liver transplants, the candidates were folic acid (32.1%), Prednisolone (20.2%), Azithromycin (1.2%), Tenofovir (5.9%), and Pantoprazole (51.2%).
Conclusion: Individuals who have received liver transplants and have a history of medication use are more susceptible to contracting COVID-19. The findings underscored the vulnerability of transplant recipients, particularly those on long-term immunosuppressive therapy, to SARS-CoV-2 infection. The prevalence of underlying diseases in both groups further emphasized the need for heightened vigilance and tailored preventive measures.
Methods: This cross-sectional study included demographic and clinical information from 170 liver transplant recipients and candidates who had sought care at the Guilan Transplant Center in Rasht, Iran. The participants' history of taking supplements, antibiotics, immunosuppressants, antiviral and gastrointestinal medications, and their COVID-19 infection history were recorded. Statistical analysis of the data was performed using SPSS software (version 22).
Results: Of the total 170 individuals in the study, 84(49.4%) were candidates for liver transplants, while 86(51.6%) had already received liver transplants. Among liver transplant candidates, 2(2.4%) were infected with COVID-19, and one died; among the liver transplant recipients, 8(9.3%) patients had COVID-19, and three died. Among liver transplant recipients, the most frequently consumed supplements, immunosuppressive, antibiotics, antiviral, and gastrointestinal medications were Vitamin D (77.9%), Prednisolone (90.1%), Cotrimoxazole (5.8%), Tenofovir (16.8%), and Pantoprazole (74.4%), respectively. Among liver transplants, the candidates were folic acid (32.1%), Prednisolone (20.2%), Azithromycin (1.2%), Tenofovir (5.9%), and Pantoprazole (51.2%).
Conclusion: Individuals who have received liver transplants and have a history of medication use are more susceptible to contracting COVID-19. The findings underscored the vulnerability of transplant recipients, particularly those on long-term immunosuppressive therapy, to SARS-CoV-2 infection. The prevalence of underlying diseases in both groups further emphasized the need for heightened vigilance and tailored preventive measures.
Type of Study: Research |
Subject:
General Surgery
Received: 2024/06/21 | Accepted: 2024/07/31 | ePublished ahead of print: 2024/11/11 | Published: 2024/11/26
Received: 2024/06/21 | Accepted: 2024/07/31 | ePublished ahead of print: 2024/11/11 | Published: 2024/11/26
References
1. Halaji M, Heiat M, Faraji N, Ranjbar R. Epidemiology of COVID-19: An updated review. J Res Med Sci. 2021;26:82. [DOI:10.4103/jrms.JRMS_506_20]
2. Zeinali T, Faraji N, Joukar F, Maroufizadeh S, Shenagari M, Naghipour M, et al. Association Between Cycle Threshold (Ct) And Clinical Outcomes In Patients With Covid-19. Stud Med Sci. 2023;34(7):397-407. [DOI:10.61186/umj.34.7.397]
3. Faraji N, Zeinali T, Joukar F, Aleali MS, Eslami N, Shenagari M, et al. Mutational Dynamics of SARS-CoV-2: Impact on Future COVID-19 Vaccine Strategies. Heliyon. 2024;10(9). [DOI:10.1016/j.heliyon.2024.e30208]
4. Zeinali T, Faraji N, Joukar F, Khan Mirzaei M, Kafshdar Jalali H, Shenagari M, et al. Gut bacteria, bacteriophages, and probiotics: Tripartite mutualism to quench the SARS-CoV2 storm. Microb Pathog. 2022;105704. [DOI:10.1016/j.micpath.2022.105704]
5. Yaghubi T, Shakoori V, Nasiri S, Keivan M, Tavakol C, Ahanjide S, et al. Clinical characteristics and outcomes of COVID-19 patients with a history of cardiovascular disease. J Curr Biomed Reports. 2022;3(1):1-7. [DOI:10.52547/jcbior.3.1.36]
6. Haghighi M, Khoshrang H, Rimaz S, Kalurazi TY, Atrkar Z, Roushan SGT, et al. Evaluation of sequential organ failure assessment (SOFA) score efficiency in predicting the mortality of intensive care unit admitted COVID-19 patients. J Curr Biomed Reports. 2021;2(4):168-175. [DOI:10.52547/JCBioR.2.4.168]
7. Kalurazi TY, Shakoori V, Nasiri S, Foumani AA, Hesni E, Mahfoozi L, et al. Clinical characteristics and laboratory findings of patients with COVID-19 in Rasht, Iran. J Curr Biomed Reports. 2022;3(2):91-97. [DOI:10.52547/JCBioR.3.2.91]
8. Banerjee D, Popoola J, Shah S, Ster IC, Quan V, Phanish M. COVID-19 infection in kidney transplant recipients. Kidney Int. 2020;97(6):1076-1082. [DOI:10.1016/j.kint.2020.03.018]
9. Sahin TT, Akbulut S, Yilmaz S. COVID-19 pandemic: Its impact on liver disease and liver transplantation. World J Gastroenterol. 2020;26(22):2987-2999. [DOI:10.3748/wjg.v26.i22.2987]
10. Zingone F, Savarino EV. Viral screening before initiation of biologics in patients with inflammatory bowel disease during the COVID-19 outbreak. lancet Gastroenterol Hepatol. 2020;5(6):525. [DOI:10.1016/S2468-1253(20)30085-6]
11. Belli LS, Duvoux C, Karam V, Adam R, Cuervas-Mons V, Pasulo L, et al. COVID-19 in liver transplant recipients: preliminary data from the ELITA/ELTR registry. Lancet Gastroenterol Hepatol. 2020;5(8):724-725. [DOI:10.1016/S2468-1253(20)30183-7]
12. Hamulka J, Jeruszka-Bielak M, Górnicka M, Drywień ME, Zielinska-Pukos MA. Dietary supplements during COVID-19 outbreak. Results of google trends analysis supported by PLifeCOVID-19 online studies. Nutrients. 2020;13(1):54. [DOI:10.3390/nu13010054]
13. Hashemi R, Montazer M, Salehi Z, Azadbakht L. Association of Recent and Long-Term Supplement Intakes With Laboratory Indices in Patients With COVID-19 in Tehran, Iran, During 2020. Front Nutr. 2022;9 :834826. [DOI:10.3389/fnut.2022.834826]
14. Alqahtani SA, Schattenberg JM. Liver injury in COVID-19: The current evidence. United Eur Gastroenterol J. 2020;8(5):509-519. [DOI:10.1177/2050640620924157]
15. Mulder MB, Borgsteede SD, Darwish Murad S, Landman CS, Metselaar HJ, Hunfeld NGM. Medication-Related Problems in Liver Transplant Recipients in the Outpatient Setting: A Dutch Cohort Study. Front Pharmacol. 2021;12:637090. [DOI:10.3389/fphar.2021.637090]
16. El Kassas M, Alboraie M, Al Balakosy A, Abdeen N, Afify S, Abdalgaber M, et al. Liver transplantation in the era of COVID-19. Arab J Gastroenterol. 2020;21(2):69-75. [DOI:10.1016/j.ajg.2020.04.019]
17. Kulkarni A V, Tevethia HV, Premkumar M, Arab JP, Candia R, Kumar K, et al. Impact of COVID-19 on liver transplant recipients-A systematic review and meta-analysis. EClinicalMedicine. 2021;38:101025. [DOI:10.1016/j.eclinm.2021.101025]
18. Lau G, Sharma M. Clinical practice guidance for hepatology and liver transplant providers during the COVID-19 pandemic: APASL expert panel consensus recommendations. Hepatol Int. 2020;14:415-428. [DOI:10.1007/s12072-020-10054-w]
19. Lavrinenko A, Kolesnichenko S, Kadyrova I, Turmukhambetova A, Akhmaltdinova L, Klyuyev D. Bacterial Co-Infections and Antimicrobial Resistance in Patients Hospitalized with Suspected or Confirmed COVID-19 Pneumonia in Kazakhstan. Pathogens. 2023;12(3):370. [DOI:10.3390/pathogens12030370]
20. Karami Z, Knoop BT, Dofferhoff ASM, Blaauw MJT, Janssen NA, van Apeldoorn M, et al. Few bacterial co-infections but frequent empiric antibiotic use in the early phase of hospitalized patients with COVID-19: results from a multicentre retrospective cohort study in The Netherlands. Infect Dis (Lond). 2021;53(2):102-110. [DOI:10.1080/23744235.2020.1839672]
21. Eggersdorfer M, Berger MM, Calder PC, Gombart AF, Ho E, Laviano A, et al. Perspective: Role of Micronutrients and Omega-3 Long-Chain Polyunsaturated Fatty Acids for Immune Outcomes of Relevance to Infections in Older Adults-A Narrative Review and Call for Action. Adv Nutr. 2022;13(5):1415-1430. [DOI:10.1093/advances/nmac058]
22. Demelash S, Takele T, Zeynu N, Temesgen S, Ayano G. Nutritional Recommendations for the Physical and Mental Health of Patients with COVID-19: Rapid Review. Heal Sci J. 2023;17(1):1-4.
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Attribution-NoneCommercial CC BY-NC
